Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Maciag · SciRah

Researcher profile · Semantic Scholar

P. Maciag

Share profile

P. Maciag — researcher profile on SciRah

h-index: 29
Works: 81
Citations: 3,281

Most-cited papers

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Shaji K. Kumar, J. Kaufman, C. Gasparetto, J. Mikhael +17 more
2017Blood487 citations
Semantic Scholar
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Shaji K. Kumar, S. Harrison, M. Cavo, J. de la Rubia +16 more
2020The Lancet Oncology331 citations
Semantic Scholar
The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix.
P. Maciag, S. Radulović, J. Rothman
2009Vaccine323 citations
Semantic Scholar
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
P. Moreau, A. Chanan-Khan, A. Roberts, A. Agarwal +15 more
2017Blood261 citations
Semantic Scholar
Targeting Bcl-2 for the treatment of multiple myeloma
C. Touzeau, P. Maciag, M. Amiot, P. Moreau
2018Leukemia118 citations
Semantic Scholar
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
J. Kaufman, C. Gasparetto, F. Schjesvold, P. Moreau +17 more
2020American journal of hematology/oncology102 citations Open access
Semantic Scholar
Development of a Listeria monocytogenes based vaccine against prostate cancer
V. Shahabi, Mariela Reyes-Reyes, Anu Wallecha, S. Rivera +2 more
2008Cancer Immunology and Immunotherapy100 citations Open access
Semantic Scholar
Cancer immunotherapy targeting the HMW-MAA protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature
P. Maciag, Matthew M. Seavey, Zhen-Kun Pan, S. Ferrone +1 more
2008Cancer Research95 citations Open access
Semantic Scholar
Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human
V. Shahabi, Matthew M. Seavey, P. Maciag, S. Rivera +1 more
2011Cancer Gene Therapy81 citations Open access
Semantic Scholar
Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment
V. Shahabi, P. Maciag, S. Rivera, Anu Wallecha
2010Bioengineered Bugs73 citations Open access
Semantic Scholar
An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse Model
Matthew M. Seavey, P. Maciag, N. Al-Rawi, D. Sewell +1 more
2009Journal of Immunology72 citations Open access
Semantic Scholar
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
P. Richardson, S. Trudel, R. Popat, M. Mateos +27 more
2023New England Journal of Medicine70 citations Open access
Semantic Scholar
Construction and Characterization of an Attenuated Listeria monocytogenes Strain for Clinical Use in Cancer Immunotherapy
Anu Wallecha, P. Maciag, S. Rivera, Y. Paterson +1 more
2008Clinical and Vaccine Immunology68 citations Open access
Semantic Scholar
HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancer.
P. S. de Araújo Souza, L. Sichero, P. Maciag
2009Future Oncology66 citations
Semantic Scholar
A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors
Matthew M. Seavey, Zhen-Kun Pan, P. Maciag, Anu Wallecha +3 more
2009Clinical Cancer Research60 citations
Semantic Scholar
Listeria-based vaccines for cancer treatment.
Y. Paterson, P. Maciag
2005Current opinion in molecular therapeutics (Print)56 citations
Semantic Scholar
Polymorphisms of the human leukocyte antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection.
P. Maciag, N. Schlecht, P. S. Souza, T. Rohan +2 more
2002Journal of Infectious Diseases56 citations Open access
Semantic Scholar
Surgical outcome in mesial temporal sclerosis correlates with prion protein gene variant
Roger Walz, R. M. Castro, T. Velasco, V. Alexandre +24 more
2003Neurology53 citations
Semantic Scholar
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma
Shannon M. Matulis, Vikas A. Gupta, P. Neri, N. Bahlis +7 more
2019Leukemia49 citations Open access
Semantic Scholar
Listeria monocytogenes-Derived Listeriolysin O Has Pathogen-Associated Molecular Pattern-Like Properties Independent of Its Hemolytic Ability
Anu Wallecha, L. Wood, Zhen-Kun Pan, P. Maciag +2 more
2012Clinical and Vaccine Immunology46 citations Open access
Semantic Scholar
DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication.
J. Boyer, T. Robinson, P. Maciag, Xiaohui Peng +8 more
2005Virology46 citations Open access
Semantic Scholar
Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study
Shaji K. Kumar, R. Vij, J. Kaufman, J. Mikhael +15 more
201641 citations
Semantic Scholar
Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
P. Moreau, S. Harrison, M. Cavo, J. de la Rubia +16 more
2019Blood38 citations
Semantic Scholar
Interaction between polymorphisms of the Human Leukocyte Antigen and HPV-16 Variants on the risk of invasive cervical cancer
P. S. de Araújo Souza, P. Maciag, K. Ribeiro, M. Petzl-Erler +2 more
2008BMC Cancer35 citations Open access
Semantic Scholar
Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics.
Anu Wallecha, K. Carroll, P. Maciag, S. Rivera +2 more
2009Advances in Applied Microbiology34 citations
Semantic Scholar
Human papillomavirus type 16 variants in cervical cancer from an admixtured population in Brazil
Katiana S Junes-Gill, L. Sichero, P. Maciag, W. Mello +2 more
2008Journal of Medical Virology32 citations
Semantic Scholar
T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study
Simon Harrison, M. Cavo, J. de la Rubia, R. Popat +18 more
2019Blood31 citations Open access
Semantic Scholar
Therapeutic cancer vaccines in cervical cancer: phase I study of Lovaxin-C.
S. Radulović, M. Branković-Magić, Emina Malisic, R. Janković +4 more
2009Journal of B.U.ON. : official journal of the Balkan Union of Oncology31 citations
Semantic Scholar
A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Shaji K. Kumar, S. Harrison, M. Cavo, J. Rubia +15 more
2019Clinical Lymphoma, Myeloma & Leukemia29 citations
Semantic Scholar
Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma
P. Moreau, A. Chanan-Khan, A. Roberts, A. Agarwal +12 more
201626 citations
Semantic Scholar
Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Shaji K. Kumar, S. Harrison, M. Cavo, J. de la Rubia +16 more
202025 citations
Semantic Scholar
Listeria monocytogenes Delivery of HPV-16 Major Capsid Protein L1 Induces Systemic and Mucosal Cell-Mediated CD4+ and CD8+ T-Cell Responses After Oral Immunization
Waleed Mustafa, P. Maciag, Zhen-Kun Pan, J. Weaver +3 more
2009Viral immunology24 citations Open access
Semantic Scholar
CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002
P. Richardson, E. Ocio, N. Raje, Tara B. Gregory +18 more
2021Blood23 citations Open access
Semantic Scholar
Deregulated Expression of Superoxide Dismutase-2 Correlates with Different Stages of Cervical Neoplasia
L. Termini, A. Longatto, P. Maciag, D. Etlinger +4 more
2011Disease Markers22 citations Open access
Semantic Scholar
Genetic susceptibility to HPV infection and cervical cancer.
P. Maciag, L. Villa
1999Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas22 citations Open access
Semantic Scholar
Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
P. Richardson, S. Trudel, H. Quach, R. Popat +15 more
2022Blood21 citations Open access
Semantic Scholar
Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results
P. Moreau, A. Chanan-Khan, A. Roberts, A. Agarwal +15 more
201519 citations
Semantic Scholar
Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia
L. Termini, P. Maciag, F. Soares, S. Nonogaki +4 more
2010International Journal of Cancer19 citations
Semantic Scholar
Rhesus macaques with high levels of vaccine induced IFN-gamma producing cells better control viral set-point following challenge with SIV239.
J. Boyer, P. Maciag, R. Parkinson, Ling Wu +3 more
2006Vaccine19 citations
Semantic Scholar
Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
J. Kaufman, C. Gasparetto, F. Schjesvold, P. Moreau +12 more
2019Blood17 citations
Semantic Scholar
A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.
M. Mateos, P. Moreau, M. Dimopoulos, Wan-Jen Hong +10 more
202015 citations
Semantic Scholar
Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results
Shaji K. Kumar, R. Vij, J. Kaufman, J. Mikhael +16 more
201515 citations
Semantic Scholar
Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.
J. Kaufman, R. Baz, S. Harrison, H. Quach +13 more
202013 citations
Semantic Scholar
Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma
J. Kaufman, C. Gasparetto, J. Mikhael, P. Moreau +14 more
201713 citations
Semantic Scholar
Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.
Shaji K. Kumar, R. Vij, J. Kaufman, J. Mikhael +16 more
201613 citations
Semantic Scholar
Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
S. Lonial, Al-Ola A. Abdallah, F. Anwer, A. Badros +12 more
2022Blood12 citations Open access
Semantic Scholar
First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma
N. Bahlis, R. Baz, S. Harrison, H. Quach +12 more
2019Blood10 citations Open access
Semantic Scholar
The Use of Living Listeria Monocytogenes as an Active Immunotherapy for the Treatment of Cancer
J. Rothman, Anu Wallecha, P. Maciag, S. Rivera +2 more
201010 citations
Semantic Scholar
Model‐based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma
Yi-Ming Cheng, Yongjun Xue, Lu-Lu Chen, Mark Masin +4 more
2022British Journal of Clinical Pharmacology8 citations Open access
Semantic Scholar
Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma
Chad C. Bjorklund, M. Amatangelo, Hsiling Chiu, Jian Kang +8 more
2021Blood8 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Moreau×19
Invite
P. Moreau — researcher profile on SciRah
J. Ross×18
Invite
J. Ross — researcher profile on SciRah
Shaji K. Kumar×16
Invite
Shaji K. Kumar — researcher profile on SciRah
Y. Paterson×12
Invite
Y. Paterson — researcher profile on SciRah

×11

Invite

C. Gasparetto — researcher profile on SciRah

Invite

C. Touzeau — researcher profile on SciRah

Invite

J. Kaufman — researcher profile on SciRah

Invite

T. Facon — researcher profile on SciRah

Invite

J. Leverson — researcher profile on SciRah

Invite

S. Harrison — researcher profile on SciRah

Invite

V. Shahabi — researcher profile on SciRah

Anu Wallecha×8

Invite

Anu Wallecha — researcher profile on SciRah